ClinicalTrials.gov record
Active, not recruiting Phase 2 Interventional

A Trial of Vigil for Participants With Ovarian Cancer

ClinicalTrials.gov ID: NCT02346747

Public ClinicalTrials.gov record NCT02346747. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 6, 2026, 8:58 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of Vigil Engineered Autologous Tumor Cell Immunotherapy in Subjects With Stage IIIb-IV Ovarian Cancer in Clinical Complete Response Following Surgery and Primary Chemotherapy

Study identification

NCT ID
NCT02346747
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 2
Lead sponsor
Gradalis, Inc.
Industry
Enrollment
92 participants

Conditions and interventions

Interventions

  • Placebo Other
  • Vigil Biological

Other · Biological

Eligibility (public fields only)

Age range
18 Years and older
Sex
Female
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 31, 2015
Primary completion
Nov 30, 2028
Completion
Nov 30, 2028
Last update posted
Oct 28, 2025

2015 – 2028

United States locations

U.S. sites
26
U.S. states
19
U.S. cities
25
Facility City State ZIP Site status
University of South Alabama Mitchell Cancer Institute Mobile Alabama 36604
Southern California Permanente Medical Group Irvine California 92618
Palo Alto Foundation Medical Group San Francisco California 94115
University Of Miami Sylvester Comprehensive Cancer Center Miami Florida 33136
Moffitt Cancer Center Tampa Florida 33612
Florida Cancer Specialists West Palm Beach Florida 33401
Georgia Cancer Center at Augusta University Augusta Georgia 30912
University Of Kentucky Markey Cancer Center Lexington Kentucky 40536
Maine Medical Center: MMP Women's Health Scarborough Maine 04074
Dana Farber Cancer Institute: Gynecologic Oncology Boston Massachusetts 02215
Henry Ford Health System Detroit Michigan 48202
Billings Clinic Billings Montana 59101
Nebraska Methodist Hospital Omaha Nebraska 68114
Dartmouth-Hitchcock Medical Center/Norris Cotton Cancer Center Lebanon New Hampshire 03756
University of New Mexico Cancer Center Albuquerque New Mexico 87106
Duke University Medical Center, Department of Medicine - Oncology Durham North Carolina 27710
Barrett Cancer Center University of Cincinnati Medical Center Cincinnati Ohio 45219
Stephenson Cancer Center at University of Oklahoma Oklahoma City Oklahoma 73104
AMD Asplundh Cancer Pavilion Abington Pennsylvania 19001
St. Luke's Health Network Bethlehem Pennsylvania 18015
Fox Chase Cancer Center Philadelphia Pennsylvania 19111
Prisma Health Cancer Institute Greenville South Carolina 29605
Mary Crowley Cancer Research Centers Dallas Texas 75230
University of Texas Southwestern Medical Center Dallas Texas 75390-9032
Cancer Care Northwest Spokane Washington 99216
Franciscan Research Center Tacoma Washington 98405

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02346747, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 28, 2025 · Synced May 6, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02346747 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →